NCT06909565ClinicalTrials.gov
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
En bref
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on…
Phase 46 000 participants recherchés153 sites1 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT06909565Ouvrir cette fiche sur ClinicalTrials.govSynchronisé avant-hier
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-04-03; recorded start 2025-07-23
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 475 other studies in this databaseCounted from the lead sponsor named in the record (Duke University)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 4 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 115 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 6,000 participants (target), run at 153 sites.
How this score is built
- Enrolment36/40
6,000 participants (target)
- Site count23/25
115 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 53 months
- Sponsor scale10/10
Duke University has led 456 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Affections
- Percutaneous Coronary Intervention
- Peripheral Endovascular Intervention
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 4 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | PREVENTION |
| Insu | QUADRUPLE (4) |
| Recrutement | 6 000 participants recherchés |
Promoteur et collaborateurs
- Duke University Promoteur
- Novartis Pharmaceuticals Collaborateurs
- Colorado Prevention Center Collaborateurs
- Mount Sinai Hospital, New York Collaborateurs
Groupes et interventions
- Inclisiran SodiumACTIVE_COMPARATOR
Inclisiran sodium 300 mg subcutaneous injection
- PlaceboPLACEBO_COMPARATOR
Normal saline 1.5 ml subcutaneous injection
Interventions
- Médicament Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
- Médicament Normal Saline (Placebo)
Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
Critères de jugement
Critère de jugement principal
Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization
MACEs include CHD death, non-fatal MI, ischemic stroke, ALI, major (above the ankle) amputation of vascular etiology, clinically driven coronary and limb revascularization.
Délai From randomization to first occurrence of MACE (up to approximately 4 years)
Critère de jugement principal
Total number of major adverse limb events (MALE) after endovascular revascularization
MALEs consist of ALI, major amputation of vascular etiology, clinically driven lower extremity peripheral revascularization.
Délai From randomization to first occurrence of MALE (up to approximately 4 years)
Critère de jugement secondaire
Number of participants with cardiovascular (CV) death
Délai From randomization to CV death (up to approximately 4 years)
Critère de jugement secondaire
Number of participants with all cause death
Délai From randomization to all cause death (up to approximately 4 years)
Critère de jugement secondaire
Number of participants with venous thromboembolic events (VTE)
Délai From randomization to first VTE (up to approximately 4 years)
Dates
| Date de début | 23 juillet 2025 (réelle) |
|---|---|
| Achèvement principal | 1 octobre 2029 (estimée) |
| Achèvement | 1 décembre 2029 (estimée) |
| Première publication | 3 avril 2025 (réelle) |
| Dernière mise à jour | 16 novembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | juillet 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
149 sites sont en recrutement
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Capital Cardiology Associates | Albany | New York | En recrutement |
| Presbyterian Heart Group | Albuquerque | New Mexico | En recrutement |
| Advanced Cardiovascular LLC | Alexander City | Alabama | En recrutement |
| Amarillo Heart Clinical Research Institute, Inc. | Amarillo | Texas | En recrutement |
| PharmaTex Research | Amarillo | Texas | En recrutement |
| AnMed Health Medical Center | Anderson | South Carolina | En recrutement |
| Asheville Cardiology Associates Research Department | Asheville | North Carolina | En recrutement |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | En recrutement |
| Austin Heart | Austin | Texas | En recrutement |
| IMS Cardiology | Avondale | Arizona | En recrutement |
| Northern Light Eastern Maine Medical Center | Bangor | Maine | En recrutement |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | En recrutement |
| Pacific Oaks Medical Group | Beverly Hills | California | En recrutement |
| Cardiology, PC | Birmingham | Alabama | En recrutement |
| Grace Research, LLC | Bossier City | Louisiana | En recrutement |
| Bridgeport Hospital | Bridgeport | Connecticut | En recrutement |
| Advanced Heart Care LLC | Bridgewater | New Jersey | En recrutement |
| Trinity Medical WNY, PC | Buffalo | New York | En recrutement |
| Sisters of Charity Hospital | Buffalo | New York | En recrutement |
| Capital Area Research LLC | Camp Hill | Pennsylvania | En recrutement |
| Aultman Hospital | Canton | Ohio | En recrutement |
| Wellspan Chambersburg Hospital | Chambersburg | Pennsylvania | En recrutement |
| Mecklenburg Heart Specialists | Charlotte | North Carolina | En recrutement |
| Novant Health Clinical Research/Heart & Vascular Institute | Charlotte | North Carolina | En recrutement |
| Atrium Health-Sanger Heart and Vascular Institute | Charlotte | North Carolina | En recrutement |
| University of Illinois Chicago | Chicago | Illinois | En recrutement |
| Cardiovascular Institute of San Diego | Chula Vista | California | En recrutement |
| Clearwater Cardiovascular Consultants | Clearwater | Florida | En recrutement |
| BayCare Medical Group | Clearwater | Florida | En recrutement |
| MedStar Southern Maryland Hospital Center | Clinton | Maryland | En recrutement |
| University of Missouri Health Care | Columbia | Missouri | En recrutement |
| John Muir Medical Center - Concord Campus | Concord | California | En recrutement |
| Javara inc. | Conroe | Texas | Retiré |
| Pioneer Clinical Studies | Coral Gables | Florida | En recrutement |
| Valley Clinical Trials | Covina | California | Retiré |
| Louisiana Heart Center | Covington | Louisiana | En recrutement |
| Nuvance Health- Danbury Hospital | Danbury | Connecticut | En recrutement |
| Cardiology Research Associates | Daytona Beach | Florida | En recrutement |
| Arrow Clinical Trails | Daytona Beach | Florida | En recrutement |
| Essentia Health-SMMC | Duluth | Minnesota | En recrutement |
| Aspirus Saint Luke's Hospital | Duluth | Minnesota | En recrutement |
| Midwest Cardiovascular Research and Education Foundation | Elkhart | Indiana | En recrutement |
| Cardiovascular Associates of the Delaware Valley | Elmer | New Jersey | En recrutement |
| Aurora Denver Cardiology Associates - Englewood | Englewood | Colorado | En recrutement |
| Javara Inc. | Fayetteville | North Carolina | En recrutement |
| Advanced Heart and Vascular Institute Of Hunterdon | Flemington | New Jersey | En recrutement |
| Northeast Georgia Heart Center, PC | Gainesville | Georgia | En recrutement |
| Stern Cardiovascular Center | Germantown | Tennessee | En recrutement |
| Thrive Clinical Research Group | Glendora | California | En recrutement |
| CHI Health Nebraska Heart | Grand Island | Nebraska | En recrutement |
103 sites supplémentaires sont indiqués dans la fiche du registre.
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 16 novembre 2026
Site ajouté
4 sites added (153 total)
149153
- 29 octobre 2026
Site ajouté
2 sites added (149 total)
147149
- 23 octobre 2026
Site ajouté
2 sites added (147 total)
145147
- 19 octobre 2026
Site ajouté
3 sites added (145 total)
142145
- 5 octobre 2026
Site ajouté
1 site added (142 total)
141142
- 28 septembre 2026
Site ajouté
2 sites added (141 total)
139141
- 22 septembre 2026
Site ajouté
1 site added (139 total)
138139
- 15 septembre 2026
Site ajouté
2 sites added (138 total)
136138
- 28 août 2026
Site ajouté
3 sites added (136 total)
133136
- 18 août 2026
Site ajouté
8 sites added (133 total)
125133
- 5 août 2026
Site ajouté
10 sites added (125 total)
115125